Sonoma Pharmaceuticals (SNOA) Net Equity Issued and Repurchased (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) posted quarterly Net Equity Issued and Repurchased of $427000.0 for Q1 2026, up 60.53% quarter-over-quarter from $266000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Net Equity Issued and Repurchased history runs 14 years deep, the most recent figure standing at $427000.0 for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $427000.0; the TTM figure through Mar 2026 stood at $693000.0 (down 63.16% YoY), while the FY2026 annual figure was $427000.0, down 86.13% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $427000.0, up from $266000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $2.9 million in Q1 2023, with the low at -$5000.0 in Q2 2023.
- The 4-year median for Net Equity Issued and Repurchased is $427000.0 (2026), against an average of $776714.3.
- Peak annual rise in Net Equity Issued and Repurchased reached 15060.0% in 2024, while the deepest fall reached 88.04% in 2024.
- Sonoma Pharmaceuticals' Net Equity Issued and Repurchased stood at -$5000.0 in 2023, then surged by 15900.0% to $790000.0 in 2024, then tumbled by 66.33% to $266000.0 in 2025, then jumped by 60.53% to $427000.0 in 2026.
- Business Quant data shows SNOA's Net Equity Issued and Repurchased at $427000.0 in Q1 2026, $266000.0 in Q4 2025, and $790000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.17 Mn | -165,129.89 | 2.58 Mn | 3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.54 Mn |
| Jun 30, 2026 | 3.54 Mn |
| Mar 31, 2026 | 427,000.00 |
| Mar 31, 2026 | 427,000.00 |
| Dec 31, 2025 | 266,000.00 |
| Dec 31, 2025 | 266,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Jun 30, 2024 | 748,000.00 |
| Jun 30, 2024 | 748,000.00 |
| Mar 31, 2024 | 343,000.00 |
| Mar 31, 2024 | 343,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Mar 31, 2023 | 2.87 Mn |
| Mar 31, 2023 | 2.87 Mn |
| Dec 31, 2021 | 662,000.00 |
| Dec 31, 2021 | 662,000.00 |
| Sep 30, 2020 | -1.49 Mn |
| Sep 30, 2020 | -1.49 Mn |